Ramucirumab: first global approval.
作者： Raewyn M. Poole , Asha Vaidya
DOI: 10.1007/S40265-014-0244-2
关键词:
摘要: … Ramucirumab has received … Ramucirumab is the first treatment to be approved by the US FDA for this setting. This article summarizes the milestones in the development of ramucirumab …
springer.com
sci-hub.se 参考文章(27)
Heather A Wakelee, Yelena Krupitskaya, Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Current opinion in investigational drugs. ,vol. 10, pp. 597- 605 ,(2009)
JR Mackey, M Ramos-Vazquez, O Lipatov, N McCarthy, D Kraznozhon, V Semiglazov, A Manikhas, K Gelmon, G Konecny, M Webster, R Hegg, S Verma, V Gorbounova, D Abi Gerges, F Thireau, H Fung, L Simms, M Buyse, A Ibrahim, M Martin, Abstract S5-04: Primary results of ROSE/TRIO-12, a randomized placebo controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer Cancer Research. ,vol. 73, ,(2013) , 10.1158/0008-5472.SABCS13-S5-04
J.A. Garcia, G. Hudes, T.K. Choueiri, W.M. Stadler, L. Wood, S. Bhatia, H. Youssoufian, E.K. Rowinsky, J.D. Schwartz, J.A. Thompson, 7108 Phase II study of IMC-1121B in patients with metastatic renal cell carcinoma (mRCC) following failure of VEGFR-2 tyrosine kinase inhibitor (TKI) therapy: interim results (IMCL CP12–0605/NCT00515697) Ejc Supplements. ,vol. 7, pp. 425- ,(2009) , 10.1016/S1359-6349(09)71441-7
Matthew C Franklin, Elizabeth C Navarro, Yujie Wang, Sheetal Patel, Pinki Singh, Yi Zhang, Kris Persaud, Amtul Bari, Heather Griffith, Leyi Shen, Paul Balderes, Paul Kussie, None, The Structural Basis for the Function of Two Anti-VEGF Receptor 2 Antibodies Structure. ,vol. 19, pp. 1097- 1107 ,(2011) , 10.1016/J.STR.2011.01.019
Catherine Frenette, Robert Gish, Targeted systemic therapies for hepatocellular carcinoma: Clinical perspectives, challenges and implications World Journal of Gastroenterology. ,vol. 18, pp. 498- 506 ,(2012) , 10.3748/WJG.V18.I6.498
Jeffrey Melson Clarke, Herbert I Hurwitz, Targeted inhibition of VEGF receptor 2: an update on ramucirumab Expert Opinion on Biological Therapy. ,vol. 13, pp. 1187- 1196 ,(2013) , 10.1517/14712598.2013.810717
Giuseppe Aprile, Marta Bonotto, Elena Ongaro, Carmelo Pozzo, Francesco Giuliani, Critical Appraisal of Ramucirumab (IMC-1121B) for Cancer Treatment: From Benchside to Clinical Use Drugs. ,vol. 73, pp. 2003- 2015 ,(2013) , 10.1007/S40265-013-0154-8
Kiyoshi Maeda, Yong-suk Chung, Yoshinari Ogawa, Soon-Myoung Kang, Masafumi Ogawa, Tetsuji Sawada, Michio Sowa, Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. ,vol. 77, pp. 858- 863 ,(1996) , 10.1002/(SICI)1097-0142(19960301)77:5<858::AID-CNCR8>3.0.CO;2-A
Judith Meza-Junco, Michael B. Sawyer, Metastatic gastric cancer – focus on targeted therapies Biologics: Targets & Therapy. ,vol. 6, pp. 137- 146 ,(2012) , 10.2147/BTT.S23917
Jerry Y. Hsu, Heather A. Wakelee, Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs. ,vol. 23, pp. 289- 304 ,(2009) , 10.2165/11317600-000000000-00000